Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and ...

COLLEGE STATION, Texas (KBTX) - The City of College Station recently recognized the month of March for National Bleeding Disorders Awareness Month, commending efforts of a Texas foundation that helps ...

The Food and Drug Administration approved Pfizer's treatment for a rare genetic bleeding disorder, making it the company's first gene therapy to win clearance in the U.S. The agency greenlighted the ...

(Reuters) -The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of treatment administered every two months for patients with the rare ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

April 26 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's (PFE.N), opens new tab gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

March is Bleeding Disorders Awareness Month. Throughout the month, the U.S. inheritable blood and bleeding disorders community has been working to inspire national conversations around these rare ...

BioTek reMEDys has identified Bleeding Disorders Awareness Month (BDAM) as an opportunity to drive change, piggybacking on the national event to call for awareness of safe medication use in patients ...

Columnist Jennifer Lynne attended 10 bleeding disorders conferences in 2025, and has some ideas about improving representation for women.